Acurx Pharmaceuticals LLC, a clinical stage, privately-held biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, announced yesterday that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI).
The product is a novel, oral antibiotic that recently entered Phase one development. It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
David P Luci, co-founder & managing partner of Acurx, said, 'FDA's granting of Fast Track designation for our lead antibiotic program validates our business model, which includes a pipeline of DNA polymerase IIIC Inhibitors we are currently developing to treat other resistant bacterial infections.'
Acurx intends to complete the drug's Phase 1 clinical trial in the second quarter of 2019 and is planning to advance ACX-362E into a Phase 2 clinical trial in the fourth quarter of 2019.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study